Whalesbook
📉 The Financial Deep Dive
The Numbers:
Wockhardt Limited has posted a robust financial performance for the third quarter and nine months ended December 31, 2025. On a standalone basis, revenue from operations in Q3 FY26 grew by a substantial 32.3% YoY to ₹430 Cr from ₹325 Cr in Q3 FY25. The most striking improvement is in net profit, which registered ₹28 Cr, a significant turnaround from a net loss of ₹22 Cr in the corresponding period last year. Standalone Earnings Per Share (EPS) improved to ₹1.73 from ₹(1.40) YoY.
For the nine months ended December 31, 2025, standalone revenue increased by 16.8% YoY to ₹1,223 Cr, with net profit showing a strong recovery to ₹150 Cr from a loss of ₹52 Cr in 9M FY25. Standalone EPS for 9M FY26 stood at ₹9.24 (vs ₹(3.36) YoY).
On a consolidated basis, Q3 FY26 revenue climbed 23.2% YoY to ₹888 Cr from ₹721 Cr in Q3 FY25. Net profit after tax witnessed a remarkable 205% jump YoY to ₹61 Cr from ₹20 Cr. Consolidated EPS rose to ₹3.61 from ₹0.91 YoY.
For the nine months, consolidated revenue was ₹2,408 Cr (YoY +6.1%). Consolidated net profit for 9M FY26 improved significantly to ₹35 Cr, a stark contrast to a net loss of ₹12 Cr in the prior nine-month period. EPS for 9M FY26 was ₹2.89 (vs ₹(1.41) YoY).
The Quality:
The company's profitability has seen marked improvement YoY, particularly on the standalone segment. The significant jump in consolidated net profit is largely driven by operational improvements and potentially better product mix, coupled with the absence of prior year's losses.
Exceptional Items:
The nine-month consolidated results include exceptional items totalling ₹107 Cr. This is primarily attributed to a ₹97 Cr charge related to the strategic decision to exit the US generic pharmaceutical business, leading to voluntary liquidation of its US subsidiaries (Morton Grove Pharmaceuticals Inc. and Wockhardt USA LLC). An additional ₹10 Cr was accounted for the incremental impact of new Indian Labour Codes.
🚩 Risks & Outlook:
While the financial results demonstrate a strong recovery and growth, the absence of specific future outlook or guidance from the management is a point of note for investors. The significant charge for exiting the US market indicates a strategic refocusing, the long-term benefits of which will be critical to monitor. The company operates solely within the Pharmaceutical business segment, making it susceptible to sector-specific regulatory changes and market dynamics. The statutory auditors have conducted a limited review of these results.